Status:
RECRUITING
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients
Lead Sponsor:
Institut Bergonié
Collaborating Sponsors:
AstraZeneca
Conditions:
Non Small Cell Lung Cancer
Advanced Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue anal...
Detailed Description
This a multicenter prospective cohort study. This study will be proposed to newly diagnosed advanced NSCLC patients. For included patients, archived paraffin embedded tumor tissue will be used for seq...
Eligibility Criteria
Inclusion
- Male or female patients aged ≥ 18 years at time of proposal study,
- Histologically confirmed non-small cell lung carcinoma,
- No previous treatment for NSCLC,
- Indication to EGFR status determination following HAS recommendation,
- Voluntary signed and dated written informed consent prior to any study specific procedure
- Patients with a social security in compliance with the French Law.
Exclusion
- Treatment for advanced NSCLC started before liquid biopsy sampling.
- Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site).
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2027
Estimated Enrollment :
580 Patients enrolled
Trial Details
Trial ID
NCT04912687
Start Date
January 1 2022
End Date
August 1 2027
Last Update
August 13 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de Cancérologie de l'Ouest - Site Paul Papin
Angers, France, 49000
2
Institut Bergonie
Bordeaux, France, 33076
3
CHRU Lille
Lille, France, 59037
4
Hospices Civils de Lyon
Lyon, France, 69002